{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:59:38Z","timestamp":1785117578092,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-026-02312-w","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:43:24Z","timestamp":1779954204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant anthracycline-free versus anthracycline-containing chemotherapy combined with dual HER2 blockade in HER2-positive breast cancer: a real-world comparative study"],"prefix":"10.1186","volume":"28","author":[{"given":"Asli","family":"Buyukkuscu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra Sucuoglu","family":"Isleyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Burak","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugay","family":"Atasever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kubra","family":"Akkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Okan","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Kulduk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Erturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Mustafa","family":"Atci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"3","key":"2312_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/CAAC.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/CAAC.21834.","journal-title":"CA Cancer J Clin"},{"issue":"4785","key":"2312_CR2","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1126\/SCIENCE.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235(4785):182\u201391. https:\/\/doi.org\/10.1126\/SCIENCE.3798106.","journal-title":"Science"},{"issue":"16","key":"2312_CR3","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMOA052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372. https:\/\/doi.org\/10.1056\/NEJMOA052306.","journal-title":"N Engl J Med"},{"issue":"15suppl","key":"2312_CR4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1200\/JCO.2011.29.15_SUPPL.1028","volume":"29","author":"G Minckwitz","year":"2011","unstructured":"Minckwitz G, Von, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, Blohmer JU, et al. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol. 2011;29(15suppl):1028\u20131028. https:\/\/doi.org\/10.1200\/JCO.2011.29.15_SUPPL.1028.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2312_CR5","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"L Gianni","year":"2016","unstructured":"Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791\u2013800. https:\/\/doi.org\/10.1016\/S1470-2045(16)00163-7.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2312_CR6","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): A phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2018;29(3):646\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdx773.","journal-title":"Ann Oncol"},{"issue":"9","key":"2312_CR7","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdt182.","journal-title":"Ann Oncol"},{"issue":"9938","key":"2312_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)62422-8.","journal-title":"Lancet"},{"issue":"2","key":"2312_CR9","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, Anthracyclines. Molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6.","journal-title":"Pharmacol Rev"},{"issue":"9","key":"2312_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/NRCARDIO.2015.65","volume":"12","author":"MS Ewer","year":"2015","unstructured":"Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12(9):547\u201358. https:\/\/doi.org\/10.1038\/NRCARDIO.2015.65.","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"2312_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj\u00e9 VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1630\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(18)30570-9.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2312_CR12","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1001\/JAMAONCOL.2021.1371","volume":"7","author":"A Van Der Voort","year":"2021","unstructured":"Van Der Voort A, Van Ramshorst MS, Van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, et al. Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial. JAMA Oncol. 2021;7(7):978\u201384. https:\/\/doi.org\/10.1001\/JAMAONCOL.2021.1371.","journal-title":"JAMA Oncol"},{"issue":"5","key":"2312_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.21037\/ATM-22-4030","volume":"11","author":"J Zhu","year":"2023","unstructured":"Zhu J, Min N, Chen Y, Li X. Neoadjuvant therapy with vs. without anthracyclines for HER2-positive breast cancer: a systematic review and meta-analysis. Ann Transl Med. 2023;11(5):200\u2013200. https:\/\/doi.org\/10.21037\/ATM-22-4030.","journal-title":"Ann Transl Med"},{"issue":"11","key":"2312_CR14","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.5858\/ARPA.2018-0902-SA","volume":"142","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, McShane LM, Hammond MEH, Allison KH, Fitzgibbons P, Press MF, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364\u201382. https:\/\/doi.org\/10.5858\/ARPA.2018-0902-SA.","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2312_CR15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/CAAC.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more personalized approach to cancer staging. CA Cancer J Clin. 2017;67(2):93\u20139. https:\/\/doi.org\/10.3322\/CAAC.21388.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2312_CR16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/JNCCN.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(5):331\u201357. https:\/\/doi.org\/10.6004\/JNCCN.2024.0035.","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"2312_CR17","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194\u2013220. https:\/\/doi.org\/10.1093\/annonc\/mdz173.","journal-title":"Ann Oncol"},{"issue":"12","key":"2312_CR18","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, et al. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020;26(12):2838\u201348. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3492.","journal-title":"Clin Cancer Res"},{"key":"2312_CR19","unstructured":"CTCAE and AE Reporting - NCI. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events. Accessed December 19, 2025."},{"issue":"4","key":"2312_CR20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.4143\/CRT.2021.901","volume":"54","author":"JY Kim","year":"2022","unstructured":"Kim JY, Nam SJ, Lee JE, Yu J, Chae BJ, Lee SK, et al. Real World Evidence of Neoadjuvant Docetaxel\/Carboplatin\/Trastuzumab\/Pertuzumab (TCHP) in Patients with HER2-Positive Early or Locally Advanced Breast Cancer: A Single-Institutional Clinical Experience. Cancer Res Treat. 2022;54(4):1091\u20138. https:\/\/doi.org\/10.4143\/CRT.2021.901.","journal-title":"Cancer Res Treat"},{"key":"2312_CR21","doi-asserted-by":"publisher","unstructured":"Jagie\u0142\u0142o-Gruszfeld AI, Rosinska M, Meluch M, Pogoda K, Niwinska A, Sienkiewicz R, et al. Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland. Cancers (Basel). 2022;14(5). https:\/\/doi.org\/10.3390\/CANCERS14051218.","DOI":"10.3390\/CANCERS14051218"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02312-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02312-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:26:08Z","timestamp":1785115568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02312-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2312"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02312-w","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"17 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Ethics Committee of Prof. Dr. Cemil Ta\u015f\u00e7\u0131o\u011flu City Hospital. (Approval No: E-48670771-514.99-286278766). Ethics approval was obtained prior to data analysis.","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"136"}}